About AOP Orphan
AOP Orphan Pharmaceuticals AG is a privately held corporation founded in Vienna in 1997. The company is dedicated to developing, marketing and distributing medicines in niche indications on a Pan-European level with special focus on Central and Eastern Europe, Middle East and Southern Asia.
Lantibio, Inc. is a development pharmaceutical company focused on discovery, development, and marketing of products for the treatment of ocular disease and serious respiratory conditions. Lantibio's lead product, Moli1901 holds an IND in CF in the US as well as Orphan Drug status in that indication.
This press release might contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from AOP Orphan's and/or Lantibio's expectations and projections. Risks and uncertainties include success of clinical trials for AOP Orphan's and/or Lantibio's products, intellectual property risks, need for additional financing or capital, ability to develop and successfully commercialize our products, ability to enter into licensing agreements, and the ability of the competition to render AOP Orphan's and/or Lantibio's product candidates or technologies obsolete or noncompetitive. AOP Orphan and Lantibio assume no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.
CONTACT: Rudolf S. Widmann, CEO of AOP Orphan Pharmaceuticals,
+43 1 50372 44, or ; Luis Molina, President-CEO ofLantibio,
+1-919-960-0217, or ; Copy Editing